Requirement 1: includes (I) an effective number of PD-L / PD-1 axis counterparts； and (II) an effective number of immunotherapeutics agents capable of activating a human plasticizer binder binder binder binder, binder binder or NK cell. 19. Claim 9: claim 8 is consolidated, and the counterparties of the PD-1 alliance are mdx-1106, Merck 3745, ct011, amp-224 or amp-514. 3. Claim 15: consolidate claim 14, and select the counterpart of PD-L1 from yw243.55.s70, mpdl3280 a, mdx-1105 and medi-4736,y MSB0010718C Reivindicaci n 20 La combinaci n de cualquiera de las reivindicaciones 1 a 18 donde dicho agente inmunoterap utico tiene una estructura de f rmula (1)a. Dashed line indicates connected or unlinked； X is s-nr1；R¹ is -W⁰-W¹-W²-W³-W⁴；W830404 is a kind of connection, tar, aluminum, tar, alcoxi or ---- tar -；W1 is a link, o-o-o-Where R2 is hydrogen, coke or sulphite； W2 is a link, or--C (o) ---C (S) - o -S (O) -W3 is a link, - N3 -.R3 is hydrogen, tar or calcium； w830808 is hydrogen, tar, acyl chloride, asphalt, propoxy, cyclopentyl, arilo ariloxi, isopropene or isopropene, which can be replaced by one or more alternatives selected from the group consisting of hydrogen oxygen, alcoxi, asphalt, dinitrile and asphalt, Bike, arilo, straight, straight, straight, straight,1. Nitro, - tar hydroxy, - tar arilo, - tar heterogeneous, - tar isomerization, - o-r8308；-O-tar-r8308；-Tar-o-r8308；--C (O) -R-Tar-c (o) r8308；-Tar-c (o) - o-r8308；--C (O) -O-R-S-R83088；--S (O) -R--NH-S (O) -R-Tar-s-r8308；-Tar-s (o) 83228r8308；-NHR8308；--NR R --NH-alquil-RHalogen, - CN, - no8322y, - SH, where r83088 is an independent hydrogen, tar, halogen, - tar hydroxy, arilo, heterogeneous, isopropene or halide； Z is hydrogen, tar, alquenilo, tar, alcoxi, arilo, halogen, isopropene, isopropyl, Each of them can be optionally replaced by one or more substitutes selected from the group, the components of which are hydroxyl, oxygen, asphalt, acylpyridan, asphalt, arilo, isopropene, isopropene, halogen, cyano
